Petra Klappers

Tumor Regression in Cancer Patients by Very Low Doses of a T Cell–Engaging Antibody

Ralf C. Bargou, Eugen Leo, Gerhard Zugmaier et al. · Science · 2008 · 1.1K citations

Life Sciences, Immunology, Oncology +17

Phase II Trial of the Anti-CD19 Bispecific T Cell–Engager Blinatumomab Shows Hematologic and Molecular Remissions in Patients With Relapsed or Refractory B-Precursor Acute Lymphoblastic Leukemia

Max S. Topp, Nicola Gökbuget, Gerhard Zugmaier et al. · Journal of Clinical Oncology · 2014 · 659 citations

Medicine, Hematology, Oncology +15

Anti-CD19 BiTE Blinatumomab Induces High Complete Remission Rate and Prolongs Overall Survival in Adult Patients with Relapsed/Refractory B-Precursor Acute Lymphoblastic Leukemia (ALL)

Max S. Topp, Nicola Goekbuget, Gerhard Zugmaier et al. · Blood · 2012 · 43 citations

Medicine, Hematology, Oncology +16

Anti-CD19 BiTE Blinatumomab Induces High Complete Remission Rate In Adult Patients with Relapsed B-Precursor ALL: Updated Results of An Ongoing Phase II Trial

Max S. Topp, Nicola Goekbuget, Gerhard Zugmaier et al. · Blood · 2011 · 32 citations

Life Sciences, Hematology, Immunology +14

Treatment of Patients with Non-Hodgkin Lymphoma (NHL) with CD19/CD3 Bispecific Antibody Blinatumomab (MT103): Double-Step Dose Increase to Continuous Infusion of 60 μg/m2/d Is Tolerable and Highly Effective

Andreas Viardot, Mariele Goebeler, Jürgen Scheele et al. · Blood · 2010 · 27 citations

Life Sciences, Immunology, Oncology +17